1. Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
- Author
-
Cristina Barca, Christoph Griessinger, Andreas Faust, Dominic Depke, Markus Essler, Albert Windhorst, Nick Devoogdt, Kevin Brindle, Michael Schäfers, Bastian Zinnhardt, Andreas Jacobs, Barca, Cristina [0000-0001-8034-2948], Devoogdt, Nick [0000-0001-9220-4833], Brindle, Kevin M [0000-0003-3883-6287], Zinnhardt, Bastian [0000-0002-8274-9108], Apollo - University of Cambridge Repository, Supporting clinical sciences, Medical Imaging, and Brindle, Kevin [0000-0003-3883-6287]
- Subjects
theranostics ,tumor ,positron emission tomography ,cell-based therapy ,Pharmaceutical Science ,Review ,molecular imaging ,gene therapy ,RS1-441 ,Pharmacy and materia medica ,Radiology Nuclear Medicine and imaging ,Drug Discovery ,Medicine ,Molecular Medicine ,radiopharmaceuticals - Abstract
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
- Published
- 2021
- Full Text
- View/download PDF